AB Science SA

0,9260

20-декабря-24 05:55:18

15 мин. задержка

Акции

+0,0270

+3,00%

Сегодняшний диапазон

0,9260 - 0,9260

ISIN

FR0010557264

Источник

Cboe

AB Science provides a summary of the webcast held on December 16, 2024

17 дек 2024 13:04:08 Источник Nasdaq GlobeNewswire
AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET

11 дек 2024 12:06:34 Источник Nasdaq GlobeNewswire
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

28 окт 2024 12:47:33 Источник Nasdaq GlobeNewswire
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

17 окт 2024 13:28:54 Источник Nasdaq GlobeNewswire
AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

10 окт 2024 02:28:04 Источник Nasdaq GlobeNewswire
AB Science announces a slight delay in the publication of its 2024 half-year financial report

30 сен 2024 12:33:35 Источник Nasdaq GlobeNewswire
AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement

26 сен 2024 02:28:30 Источник Nasdaq GlobeNewswire
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024

23 сен 2024 11:51:06 Источник Nasdaq GlobeNewswire
AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19

08 июл 2024 01:56:02 Источник Nasdaq GlobeNewswire
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

28 июн 2024 06:31:02 Источник Nasdaq GlobeNewswire
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS

31 май 2024 10:30:34 Источник Nasdaq GlobeNewswire
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

29 май 2024 12:02:52 Источник Nasdaq GlobeNewswire
AB Science reports its revenues for the year 2023 and provides an update on its activities

15 май 2024 14:16:47 Источник Nasdaq GlobeNewswire
AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036

13 май 2024 12:08:35 Источник Nasdaq GlobeNewswire
AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient

07 май 2024 12:05:45 Источник Nasdaq GlobeNewswire
AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science

02 май 2024 13:14:41 Источник Nasdaq GlobeNewswire
AB Science announces a slight delay in the publication of its 2023 annual financial report

30 апр 2024 12:56:04 Источник Nasdaq GlobeNewswire
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS

03 апр 2024 12:08:55 Источник Nasdaq GlobeNewswire
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

13 мар 2024 07:58:59 Источник Nasdaq GlobeNewswire
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

07 мар 2024 09:20:57 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.